A protein kinase inhibitor, fasudil (AT-877): A novel approach to signal transduction therapy

Cardiovascular Drug Reviews

Volumn 16, Issue 1, 1998, Pages 76-87

  Asano, Toshio ^a   Ikegaki, Ichiro ^a   Satoh, Shin Ichi ^a   Seto, Minoru ^a   Sasaki, Yasuharu ^a  

^a ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

AT 877; Coronary diseases; Fasudil; HA 1077; Protein kinase inhibitors; Stroke; Vasospasm

Indexed keywords

FASUDIL; MYOSIN LIGHT CHAIN; PROTEIN KINASE;

ARTERY DILATATION; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY; DOG; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SUBARACHNOID HEMORRHAGE; SWINE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASOSPASM;

EID: 0031877977     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1998.tb00346.x     Document Type: Article

References (37)

1. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm: A controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619-624.
2. Arai M, Sasaki Y, Nozawa R. Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem Pharmacol 1993;46:1487-1490.
3. Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241:1033-1040.
4. Asano T, Ikegaki I, Satoh S, et al. Endothelin: A potential modulator of cerebral vasospasm. Eur J Pharmacol 1990;190:365-372.
5. Asano T, Ikegaki I, Satoh S, et al. Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain. Br J Pharmacol 1991;103:1935-1938.
6. Asano T, Suzuki T, Tsuchiya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 1989;98:1091-1100.
7. Butler WE, Peterson JW, Zervas NT, et al. Intracellular calcium, myosin light chain phosphorylation, and contractile force in experimental cerebral vasospasm. Neurosurgery 1996;38:781-788.
8. Haley EC, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in North America. J Neurosurg 1997;86:464-474.
9. Harada T, Seto M, Sasaki Y, et al. The time course of myosin light-chain phosphorylation in blood-induced vasospasm. Neurosurgery 1995;36:1182-1183.
10. Hidaka M, Inagaki M, Kawamoto S, et al. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984;22:5036-5041.
11. Hidaka H, Kobayashi R. Pharmacology of protein kinase inhibitors. Annu Rev Pharmacol Toxicol 1992; 32:377-397.
12. Hunter T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 1995;80:225-236.
13. Kamm KE, Stull JT. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu Rev Pharmacol Toxicol 1985;25:593-620.
14. Kassell NF, Haley ECJ, Apperson-Hansen C, et al. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84:221-228.
15. Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β. Circulation 1997;96:4357-4363.
16. Levitzki A. Signal-transduction therapy. Eur J Biochem 1994;226:1-13.
17. Morikawa A, Sone T, Asano T. 5-isoquinolinesulfonamide derivatives. 1. Synthesis and vasodilatory activity of N-(2-guanidinoethyl)-5-isoquinolinesuifonamide derivatives. J Med Chem 1989;32:42-46.
18. Morikawa A, Sone T, Asano T. 5-isoquinolinesulfonamide derivatives. 2. Synthesis and vasodilatory activity of N-(2-aminoethyl)-5-isoquinolinesulfonamide derivatives. J Med Chem 1989;32:46-50.
19. Ohtaki M, Tranmer B. Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877. Stroke 1994;25:1234-1240.
20. Pawson T. Protein modules and signalling networks. Nature 1995;373:573-579.
21. Sakurada K, Ikuhara T, Seto M, et al. An antibody for phosphorylated myosin light chain of smooth muscle: Application to a biochemistry study. J Biochem 1994;115:18-21.
22. Sasaki Y, Sasaki Y. Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilator. Biochem Biophys Res Commun 1990;171:1182-1187.
23. 2+ channel antagonist and vasodilator, on chronic cerebral vasospasm. Eur J Pharmacol 1992;220:243-248.
24. Satoh S, Suzuki Y, Ikegaki I, et al. The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs. Acta Neurochir 1991;110:185-188.
25. Seto M, Sasaki Y, Sasaki Y, Hidaka H. Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. Eur J Pharmacol 1991;195:267-272.
26. Shibuya M, Suzuki Y, Sugita K, et al. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage. Acta Neurochir 1990; 107:11-15.
27. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachonid hemorrhage (results of a prospective placebo-controlled double-blind trial). J Neurosurg 1992; 76:571-577.
28. Shibuya M, Suzuki Y, Takayasu M, et al. The effects of an intraceuular calcium antagonist HA1077 on delayed cerebral vasospasm in dogs. Acta Neurochir 1988;90:53-59.
29. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994;372:231-236.
30. Suzuki Y, Satoh S, Kimura M, et al. Effects of vasopressin and oxytocin on canine cerebral circulation in vivo. J Neurosurg 1992;77:424-431.
31. Suzuki Y, Shibuya M, Takayasu M, et al. Protein kinase activity in canine basilar arteries after subarachnoid hemorrhage. Neurosurgery 1988;22:1028-1031.
32. Takayasu M, Dacey RGJ. Effects of HA1077, a novel calcium antagonistic spasmolytic agent on intracerebral arterioles of rats. Acta Neurochir 1990;103:67-70.
33. Takayasu M, Suzuki Y, Shibuya M, et al. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg 1986;65:80-85.
34. 2+ level and contraction in vascular smooth muscle. Eur J Pharmacol 1993;250:431-437.
35. Takuwa Y, Matsui T, Abe Y, et al. Alterations in protein kinase C activity and membrane lipid metabolism in cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1993;13:409-415.
36. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994.
37. Varsos VG, Liszczak TM, Han PH, et al. Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a two-hemorrhage canine model. J Neurosurg 1983;58:11-17.